Table 1.
Characteristics of Cohort I, II, IV, and V
| Variable | Cohort I (n = 233) |
Cohort II (n = 291) |
Cohort IV(n = 221) |
Cohort V (n = 97) |
||||
|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | No. | % | |
| Discrete | ||||||||
| Center | ||||||||
| Fox Chase Cancer Center | 64 | 27 | — | — | — | — | — | — |
| Kaiser Permanente | 79 | 34 | — | — | — | — | — | — |
| University of Miami | 30 | 13 | — | — | — | — | — | — |
| Washington University | 60 | 26 | — | — | — | — | — | — |
| Race | ||||||||
| Asian | 1 | 0.4 | — | — | — | — | — | — |
| Black | 16 | 7 | 3 | 1 | — | — | — | — |
| White | 216 | 93 | 287 | 99 | — | — | — | — |
| Other | — | — | 1 | 0.3 | — | — | — | — |
| Unknown | — | — | — | — | 221 | 100 | 97 | 100 |
| Age, years | ||||||||
| < 50 | 42 | 18 | 86 | 30 | 27 | 12 | 6 | 6 |
| ≥ 50 | 191 | 82 | 205 | 70 | 194 | 88 | 91 | 94 |
| Tumor size, cm | ||||||||
| < 2 | 117 | 50 | 114 | 39 | 53 | 24 | 39 | 40 |
| ≥ 2-< 5 | 107 | 46 | 133 | 46 | 142 | 64 | 43 | 44 |
| ≥ 5 | 9 | 4 | 33 | 11 | 23 | 10 | 11 | 11 |
| Missing | — | — | 11 | 4 | 3 | 1 | 4 | 4 |
| Grade | ||||||||
| 1 | 61 | 26 | 67 | 23 | 56 | 25 | 14 | 14 |
| 2 | 104 | 45 | 137 | 47 | 99 | 45 | 47 | 48 |
| 3 | 68 | 29 | 48 | 16 | 66 | 30 | 32 | 33 |
| Missing | — | — | 39 | 13 | — | — | 4 | 4 |
| ER status | ||||||||
| Negative | 44 | 19 | 97 | 33 | 44 | 20 | 11 | 11 |
| Positive | 186 | 80 | 163 | 56 | 130 | 59 | 80 | 82 |
| Missing | 3 | 1 | 31 | 11 | 47 | 21 | 6 | 6 |
| PR status | ||||||||
| Negative | 65 | 28 | 103 | 35 | 87 | 39 | 25 | 26 |
| Positive | 122 | 52 | 151 | 52 | 134 | 61 | 67 | 69 |
| Missing | 46 | 20 | 37 | 13 | — | — | 5 | 5 |
| HER2 status | ||||||||
| Normal | — | — | 217 | 75 | 173 | 78 | 77 | 79 |
| Overexpressed | — | — | 33 | 11 | 29 | 13 | 13 | 13 |
| Missing | — | — | 41 | 14 | 19 | 9 | 7 | 7 |
| Node status | ||||||||
| Negative | 233 | 100 | 291 | 100 | 70 | 32 | 42 | 43 |
| Positive | 0 | 0 | 0 | 0 | 138 | 62 | 42 | 43 |
| Missing | — | — | — | — | 13 | 6 | 13 | 13 |
| Chemotherapy | ||||||||
| Untreated | 233 | 100 | — | — | 171 | 77 | 95 | 98 |
| Treated | 0 | 0 | — | — | 45 | 20 | 1* | 1 |
| Missing | — | — | — | — | 5 | 2 | 1 | 1 |
| Hormone therapy | ||||||||
| Untreated | 233 | 100 | — | — | 0 | 0 | 5 | 5 |
| Treated | 0 | 0 | — | — | 221 | 100 | 92 | 95 |
| Radiation therapy | ||||||||
| Untreated | 187 | 80 | — | — | 221 | 100 | 36 | 37 |
| Treated | 46 | 20 | — | — | 0 | 0 | 59 | 61 |
| Missing | — | — | — | — | — | — | 2 | 2 |
| CSS events | 52 | 22 | 107 | 37 | 65 | 29 | 56 | 58 |
| Nuc-pYStat5 status | ||||||||
| Low | 129 | 55 | 84 | 29 | 93 | 42 | 10 | 10 |
| High | 94 | 40 | 114 | 39 | 73 | 33 | 55 | 57 |
| Missing | 10 | 4 | 93 | 32 | 55 | 25 | 32 | 33 |
| Mean | Median | Range | SD | |
|---|---|---|---|---|
| Continuous | ||||
| Cohort I | ||||
| Age at diagnosis | 62.3 | 62 | 31-88 | 12.9 |
| Tumor size, cm | 2.08 | 1.8 | 0.6-7.5 | 1.07 |
| Follow-up, months | 129 | 126 | 3-326 | 71 |
| Nuc-pYStat5 score | 5.0 | 0 | 0-40 | 8.6 |
| Year of diagnosis | — | — | 1974-1990 | — |
| Cohort II | ||||
| Age at diagnosis | 57.3 | 57 | 24-86 | 12.3 |
| Tumor size, cm | 2.53 | 2.0 | 0.4-11 | 1.67 |
| Follow-up, months | 165 | 160 | 1-425 | 106 |
| Nuc-pYStat5 score | 852 | 771 | 265-2,236 | 416 |
| Year of diagnosis | — | — | 1953-1980 | — |
| Cohort IV | ||||
| Age at diagnosis | 63.3 | 63 | 35-97 | 12.1 |
| Tumor size, cm | 3.0 | 2.5 | 0.5-13.0 | 1.8 |
| Follow-up, months | 59.0 | 60 | 2-137 | 28.0 |
| Nuc-pYStat5 score | 1 | 0 | 0-4 | 1.3 |
| Positive nodes | 3.8 | 1 | 0-38 | 6.2 |
| Year of diagnosis | — | — | 1985-1996 | — |
| Cohort V | ||||
| Age at diagnosis | 69.8 | 72 | 38-89 | 11.0 |
| Tumor size, cm | 2.7 | 2.1 | 0.4-11 | 1.7 |
| Follow-up, months | 57.5 | 40.7 | 3.6-143 | 40.9 |
| Nuc-pYStat5 score | 1,262 | 1,027 | 533-4,243 | 762 |
| Positive nodes | 2.3 | 0 | 0-22 | 3.7 |
| Year of diagnosis | — | — | 1990-2000 | — |
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; CSS, cancer-specific survival; SD, standard deviation; Nuc-pYStat5, nuclear localized and tyrosine phosphorylated Stat5.
*
Patient received chemotherapy after disease relapse.